Advanced Solid Tumors Clinical Trials in Grand Rapids, Michigan

16 studies are recruiting for advanced solid tumors in Grand Rapids, Michigan right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. A Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of VVD-133214 as Monotherapy and in Combination in Participants With Advanced Solid Tumors

   This is a first-in-human, Phase I, open-label, multicenter, dose-escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity of VVD-133214 monotherapy, and in combination with bevacizumab or pembrolizumab, in part…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   START Midwest, Grand Rapids, Michigan

   Locations

   47 in total

   Run by

   Vividion Therapeutics, Inc.

   See if you can join NCT06004245 on ClinicalTrials.gov

2. Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors

   The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of RMC-5127 as a monotherapy and in combination with either daraxonrasib or cetuximab in adults with KRAS G12V-mutant solid tumors.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   START Midwest, Grand Rapids, Michigan

   Locations

   9 in total

   Run by

   Revolution Medicines, Inc.

   See if you can join NCT07349537 on ClinicalTrials.gov

3. A Study of Calderasib (MK-1084) in KRAS Mutant Advanced Solid Tumors (MK-1084-001)

   This is a study evaluating the safety, pharmacokinetics, and efficacy of calderasib alone, and calderasib plus other combination therapies in participants with advanced solid tumors with identified kirsten rat sarcoma viral oncogene homolog G12C (KRAS G12C) mutation.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   START Midwest ( Site 0267), Grand Rapids, Michigan

   Locations

   75 in total

   Run by

   Merck Sharp & Dohme LLC

   See if you can join NCT05067283 on ClinicalTrials.gov

4. A Study of PARG Inhibitor FORX-428 in Patients With Advanced Solid Tumors.

   The goal of this interventional study is to evaluate the safety and tolerability of escalating doses of FORX-428 as monotherapy in patients with select advanced solid tumors with BRCA1/2 mutations or other DDR deficiencies or high replication stress, and to determine the maximum tolerated dose (MTD…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   START - Midwest, Grand Rapids, Michigan

   Locations

   8 in total

   Run by

   FoRx Therapeutics AG

   See if you can join NCT07356453 on ClinicalTrials.gov

5. Trial to Evaluate the Safety and Preliminary Efficacy of GEN1079 in Participants With Advanced Solid Tumors

   The purpose of this trial is to learn about the safety and effectiveness of the antibody GEN1079 in participants with certain types of cancer. The trial has multiple parts. The first part of the trial tests different doses of GEN1079 to find out if it is safe and determine what are the best doses t…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   START Midwest, LLC, Grand Rapids, Michigan

   Locations

   12 in total

   Run by

   Genmab

   See if you can join NCT07387068 on ClinicalTrials.gov

6. TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer

   The purpose of the study is to learn from the real world practice of prescribing targeted therapies to patients with advanced cancer whose tumor harbors a genomic variant known to be a drug target or to predict sensitivity to a drug. NOTE: Due to character limits, the arms section does NOT include …

   Stage

   Phase 2

   Ages

   12 and older

   Site

   Cancer Research Consortium of West Michigan, Grand Rapids, Michigan

   Locations

   181 in total

   Run by

   American Society of Clinical Oncology

   See if you can join NCT02693535 on ClinicalTrials.gov

7. First-in-Human Trial of VBC108 in Participants With Advanced Malignant Solid Tumors

   This is a multicenter, open-label, multiple-dose, FIH Phase 1/2a trial. The Phase 1 portion uses Bayesian optimal interval (BOIN) design to escalate and determine the MTD and/or RP2D with potential backfill cohorts. The Phase 2a portion consists of dose optimization followed by cohort expansion to …

   Stage

   Phase 1

   Ages

   18 and older

   Site

   START Midwest, LLC, Grand Rapids, Michigan

   Locations

   12 in total

   Run by

   VelaVigo Bio Inc

   See if you can join NCT07700160 on ClinicalTrials.gov

8. A Study of JNJ-87890387 for Advanced Solid Tumors

   The purpose of this study is to determine safety and recommended phase 2 dose(s) (RP2Ds) of JNJ-87890387 and to determine the safety of JNJ-87890387 at the RP2D(s).

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Start Midwest, Grand Rapids, Michigan

   Locations

   6 in total

   Run by

   Janssen Research & Development, LLC

   See if you can join NCT06178614 on ClinicalTrials.gov

9. A Study of OTP-01, a Dual Paratopic PD-1/VEGFR2 Antibody, in Patients With Advanced Solid Tumors

   The main goals of this clinical trial are to find out what the best dose of the study drug, OTP-01, is for patients with solid tumors through understanding how it is tolerated and any side effects that it may cause. The trial will also see if OTP-01 causes tumors to shrink and how the body processe…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   South Texas Accelerated Research Therapeutics (START) Midwest, Grand Rapids, Michigan

   Locations

   14 in total

   Run by

   Ottimo Pharma Limited

   See if you can join NCT07266428 on ClinicalTrials.gov

10. A Study of PHST001 in Advanced Solid Tumors

    This is a multi-center, first-in-human (FIH), open-label, Phase 1a/1b dose escalation and dose expansion study to assess the safety, PK, pharmacodynamics, and antitumor activity of PHST001 monotherapy (Phase 1a) or in combination with chemotherapy (Phase 1b) in adult participants with advanced rela…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    START Center for Cancer Research - Midwest, Grand Rapids, Michigan

    Locations

    20 in total

    Run by

    Pheast Therapeutics

    See if you can join NCT06840886 on ClinicalTrials.gov

11. A Study of mRNA-4106 or mRNA-4200 Administered Alone or in Combination With Anti-Cancer Agents in Participants With Solid Tumors

    The purpose of this study is to assess the safety and tolerability of mRNA-4106 monotherapy and of mRNA-4200 in combination with checkpoint inhibitor therapy in participants with solid tumors.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    START Midwest, Grand Rapids, Michigan

    Locations

    4 in total

    Run by

    ModernaTX, Inc.

    See if you can join NCT06880549 on ClinicalTrials.gov

12. Study of GS-2426 in Participants With Advanced Solid Tumors

    The goal of this clinical study is to learn more about the study drug GS-2426, and how safe and tolerable it is in participants with advanced methylthioadenosine phosphorylase (MTAP)-deleted solid tumors. The primary objective of this study is to evaluate the safety and tolerability of GS-2426 in p…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    START Midwest, Grand Rapids, Michigan

    Locations

    4 in total

    Run by

    Gilead Sciences

    See if you can join NCT07601243 on ClinicalTrials.gov

13. A Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid Tumors

    To evaluate the safety, tolerability, and DLTs and determine the MTD and/or RDE(s) of INCA33890 in participants with select advanced or metastatic solid tumors.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Cancer and Hematology Centers of Western Michigan-Start Midwest, Grand Rapids, Michigan

    Locations

    39 in total

    Run by

    Incyte Corporation

    See if you can join NCT05836324 on ClinicalTrials.gov

14. A First-In Human (FIH) Study to Find Out How Well REGN10597 Medicine Given Alone or in Combination With Cemiplimab Works in Adult Participants Who Have Cancer With Tumors That Have Spread in Their Body

    This study is researching an experimental drug called REGN10597 alone or in combination with another drug called cemiplimab (called "study drug(s)"). The study is focused on patients with certain solid tumors that are in an advanced stage. The aim of the study is to see how safe, tolerable, and eff…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Start Midwest Cancer Research, Grand Rapids, Michigan

    Locations

    11 in total

    Run by

    Regeneron Pharmaceuticals

    See if you can join NCT06413680 on ClinicalTrials.gov

15. A Study of MGC028 in Participants With Advanced Solid Tumors

    The goal of this clinical trial is to characterize the safety, tolerability, dose-limiting toxicities (DLT), and maximum tolerated dose (MTD) or maximum administered dose of MGC028 (if no MTD is defined). The study will enroll adult participants with relapsed or refractory, unresectable, locally ad…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    South Texas Accelerated Research Therapeutics (START) Midwest, Grand Rapids, Michigan

    Locations

    7 in total

    Run by

    MacroGenics

    See if you can join NCT06723236 on ClinicalTrials.gov

16. A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-159642 in Participants With Advanced Solid Tumors

    A FIH study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary anti-tumor activity of VVD-159642, a rat sarcoma viral oncogene-phosphatidylinositol 3-kinase alpha (RAS-PI3Kα) inhibitor, as a single agent and in combination with either sotorasib or tr…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    START Mid West, Grand Rapids, Michigan

    Locations

    9 in total

    Run by

    Vividion Therapeutics, Inc.

    See if you can join NCT06804824 on ClinicalTrials.gov